{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:20:30Z","timestamp":1787750430152,"version":"build-2784847793"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Although some children with B-cell acute lymphoblastic leukemia (B-ALL) receive intravenous immunoglobulin (IVIG) during conventional therapy, supplementation practices vary, and data describing the indications and their impact are lacking. In this single-institution cohort of children with B-ALL receiving conventional chemotherapy, we evaluate associations of patient and disease characteristics with IVIG supplementation, describe infection-related outcomes by IVIG receipt, and describe outcomes after IVIG supplementation. Multivariable logistic regression models identified factors associated with IVIG receipt. Of 373 eligible patients with B-ALL who did not receive immune therapy, 251 (67.3%) had an IgG level checked, and 114 (30.6%) received IVIG. The median IgG nadir was lower in IVIG recipients versus nonrecipients (404 vs. 675\u00a0mg\/dL,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.01). IVIG recipients were younger at diagnosis (4 vs. 6\u00a0y,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.01) and had a larger number of severe infections per 1000 leukemia treatment days (4.2 vs. 2.5,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.01). In adjusted models, the odds of IVIG administration were lower for non-white patients (OR=0.43, 95% CI=0.22-0.83), higher for patients with &gt;2 severe infections during treatment (OR=2.57, 95% CI=1.28-5.18), and higher for National Cancer Institute standard risk patients with IgG nadir &lt;500\u00a0mg\/dL (OR=7.45, 95% CI=3.54-15.70). For IVIG recipients, the rate of emergency department visits, severe infections, and febrile neutropenia episodes was 5.4, 1.9, and 1.1 per 1000 treatment days, respectively, during IVIG supplementation. Among children with B-ALL receiving conventional chemotherapy, clinical characteristics differ between IVIG recipients and nonrecipients. Uniform IgG measurements during therapy may guide supplementation decisions, especially in the era of frontline immunotherapy.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003203","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:01:20Z","timestamp":1782237680000},"page":"e175-e182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-5917","authenticated-orcid":false,"given":"Holly J.","family":"Edington","sequence":"first","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta"},{"name":"Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-639X","authenticated-orcid":false,"given":"Nicholas P.","family":"DeGroote","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-9932","authenticated-orcid":false,"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta"},{"name":"Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-5376","authenticated-orcid":false,"given":"Tamara P.","family":"Miller","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta"},{"name":"Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-2002","authenticated-orcid":false,"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center at Children\u2019s Healthcare of Atlanta"},{"name":"Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"R1-20260703","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdw557","article-title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","volume":"28","author":"Inaba","year":"2017","journal-title":"Ann Oncol"},{"issue":"3S","key":"R3-20260703","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R4-20260703","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R5-20260703","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"R6-20260703","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20260703","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"R8-20260703","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20260703","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"R10-20260703","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"R11-20260703","doi-asserted-by":"crossref","first-page":"e31779","DOI":"10.1002\/pbc.31779","article-title":"Hypogammaglobulinemia in children receiving targeted immunotherapies for B-lineage malignancies: practical guidance for assessment and management","volume":"72","author":"Long","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20260703","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/clinchem\/28.1.126","article-title":"Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry","volume":"28","author":"Jolliff","year":"1982","journal-title":"Clin Chem"},{"key":"R15-20260703","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MPH.0000000000001415","article-title":"Impact of IgG monitoring and IVIG supplementation on the frequency of febrile illnesses in pediatric acute lymphoblastic leukemia patients undergoing maintenance chemotherapy","volume":"41","author":"Holmes","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20260703","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-141","article-title":"Prevalence and safety of intravenous immunoglobulin administration during maintenance chemotherapy in children with acute lymphoblastic leukemia in first complete remission: a health maintenance organization perspective","volume":"22","author":"Van Winkle","year":"2018","journal-title":"Perm J"},{"key":"R17-20260703","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R18-20260703","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"R19-20260703","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.1992.03490040059026","article-title":"Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)\/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group","volume":"268","author":"Mofenson","year":"1992","journal-title":"JAMA"},{"key":"R20-20260703","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"2024","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20260703","first-page":"CD001239","article-title":"Intravenous immunoglobulin for suspected or subsequently proven infection in neonates","author":"Ohlsson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20260703","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/cncr.34476","article-title":"Infectious events in pediatric patients with acute lymphoblastic leukemia\/lymphoma undergoing evaluation for fever without severe neutropenia","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"R23-20260703","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.aller.2020.05.008","article-title":"Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement","volume":"48","author":"Ibis","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"R24-20260703","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dmcn.13159","article-title":"Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome","volume":"58","author":"Nosadini","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"R25-20260703","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"R26-20260703","doi-asserted-by":"crossref","first-page":"e0227796","DOI":"10.1371\/journal.pone.0227796","article-title":"Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children","volume":"15","author":"Kubota","year":"2020","journal-title":"PLoS One"},{"key":"R27-20260703","doi-asserted-by":"crossref","first-page":"e28260","DOI":"10.1002\/pbc.28260","article-title":"Dealing with a critical national shortage-approaches to triaging immune globulin supply in pediatric hematology and oncology","volume":"67","author":"Edington","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20260703","doi-asserted-by":"crossref","first-page":"105868","DOI":"10.1016\/j.intimp.2019.105868","article-title":"Changing trends in IVIG use in pediatric patients: a retrospective review of practices in a network of major USA pediatric hospitals","volume":"76","author":"Balch","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"R29-20260703","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R31-20260703","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2020.03.018","article-title":"Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race","volume":"125","author":"Harkness","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R32-20260703","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fonc.2020.01022","article-title":"The contribution of race to breast tumor microenvironment composition and disease progression","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"R33-20260703","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/cam4.3753","article-title":"Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities","volume":"10","author":"Curran","year":"2021","journal-title":"Cancer Med"},{"key":"R34-20260703","doi-asserted-by":"crossref","first-page":"e004774","DOI":"10.1136\/jitc-2022-004774","article-title":"Association of race\/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia","volume":"10","author":"Gilbert","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R35-20260703","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.1016\/j.blre.2019.06.003","article-title":"Benign ethnic neutropenia","volume":"37","author":"Atallah-Yunes","year":"2019","journal-title":"Blood Rev"},{"key":"R36-20260703","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1002\/cncr.31560","article-title":"Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival?","volume":"124","author":"Kehm","year":"2018","journal-title":"Cancer"},{"key":"R37-20260703","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2014-01-552166","article-title":"6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"124","author":"Bhatia","year":"2014","journal-title":"Blood"},{"key":"R38-20260703","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"key":"R39-20260703","doi-asserted-by":"crossref","first-page":"e1750","DOI":"10.1200\/OP.22.00344","article-title":"Real-world cost of pediatric acute lymphoblastic leukemia care among commercially insured individuals in the United States: effect of era and age at diagnosis","volume":"18","author":"Turcotte","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"R40-20260703","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pbc.23258","article-title":"Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases","volume":"58","author":"van Tilburg","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R41-20260703","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPH.0000000000000697","article-title":"Immune dysfunction after completion of childhood leukemia therapy","volume":"39","author":"Perkins","year":"2017","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:42Z","timestamp":1787747622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003203","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2025-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}